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Modification of the transcriptomic response to renal ischemia/
reperfusion injury by lipoxin analog.
Background. Lipoxins are lipoxygenase-derived eicosanoids
with anti-inflammatory and proresolution bioactivities in vitro
and in vivo. We have previously demonstrated that the stable
synthetic LXA4 analog 15-epi-16-(FPhO)-LXA4-Me is reno-
protective in murine renal ischemia/reperfusion injury, as
gauged by lower serum creatinine, attenuated leukocyte infil-
tration, and reduced morphologic tubule injury.
Methods. We employed complementary oligonucleotide mi-
croarray and bioinformatic analyses to probe the transcripto-
mic events that underpin lipoxin renoprotection in this setting.
Results. Microarray-based analysis identified three broad
categories of genes whose mRNA levels are altered in response
to ischemia/reperfusion injury, including known genes previously
implicated in the pathogenesis of ischemia/reperfusion injury
[e.g., intercellular adhesion molecule-1 (ICAM-1), p21, KIM-1],
known genes not previously associated with ischemia/reper-
fusion injury, and cDNAs representing yet uncharacterized
genes. Characterization of expressed sequence tags (ESTs) dis-
played on microarrays represents a major challenge in studies
of global gene expression. A bioinformatic annotation pipeline
successfully annotated a large proportion of ESTs modulated
during ischemia/reperfusion injury. The differential expression
of a representative group of these ischemia/reperfusion injury–
modulated genes was confirmed by real-time polymerase chain
reaction. Prominent among the up-regulated genes were clau-
din-1, -3, and -7, and ADAM8. Interestingly, the former re-
sponse was claudin-specific and was not observed with other
claudins expressed by the kidney (e.g., claudin-8 and -6) or
indeed with other components of the renal tight junctions (e.g.,
occludin and junctional adhesion molecule). Noteworthy among
the down-regulated genes was a cluster of transport proteins
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(e.g., aquaporin-1) and the zinc metalloendopeptidase meprin-
1 implicated in renal remodeling.
Conclusion. Treatment with the lipoxin analog 15-epi-16-
(FPhO)-LXA4-Me prior to injury modified the expression of
many differentially expressed pathogenic mediators, including
cytokines, growth factors, adhesion molecules, and proteases,
suggesting a renoprotective action at the core of the pathophys-
iology of acute renal failure (ARF). Importantly, this lipoxin-
modulated transcriptomic response included many genes ex-
pressed by renal parenchymal cells and was not merely a reflection
of a reduced renal mRNA load resulting from attenuated leu-
kocyte recruitment. The data presented herein suggest a frame-
work for understanding drivers of kidney injury in ischemia/
reperfusion and the molecular basis for renoprotection by li-
poxins in this setting.
Ischemic acute renal failure (ARF) remains a formida-
ble clinical problem that is associated with high morbid-
ity and mortality [1, 2]. The pathophysiology of ARF is
complex and multipronged and includes persistent intra-
renal vasoconstriction, hypoxic injury to microvascular
endothelial cells and tubule epithelial cells, and leuko-
cyte-mediated cytotoxicity [1–3]. Despite the impressive
efficacy of agents that target these events in experimental
models, none has proved as effective as monotherapy in
randomized, controlled clinical trials [1, 2]. Accordingly,
attention has shifted toward therapeutic interventions
that simultaneously target two or more of the aforemen-
tioned pathophysiologic events.
Lipoxins are lipoxygenase-derived arachidonate me-
tabolites that are formed predominantly through cell-
cell interactions in many human and experimental in-
flammatory, hypersensitivity, and vascular diseases [4, 6].
The spectrum of bioactivities reported for lipoxins in
vitro and in vivo suggests that these lipid mediators may
be protective in renal ischemia/reperfusion injury. Lipox-
ins are potent intrarenal vasodilators that inhibit poly-
morphonuclear cells (PMNs) chemotaxis, adhesion and
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migration across the endothelium and epithelium, pro-
mote clearance of apoptotic PMNs, and modulate several
cytokine responses [4–13]. Cyclooxygenase-2 (COX-2),
when acetylated by aspirin, catalyzes the generation of
15R-HETE from arachadonic acid [4]. 15R-HETE is
then converted by leukocytes to 15R epimers of lipoxins
[aspirin-triggered lipoxins (ATLs)] during cell interac-
tions [3]. ATLs share many of the anti-inflammatory and
proresolution properties of native lipoxins in vitro [4].
Analogs of LXA4 and LXB4 (the major mammalian li-
poxin) and of ATLs have been synthesized that are rela-
tively resistant to degradation [4].
Importantly, they display many of the biologic proper-
ties of native lipoxins and ATLs in vitro and are potential
prototype therapeutics [14]. Native LXA4, ATLs, and
several synthetic lipoxin analogs have already been dem-
onstrated to have impressive anti-inflammatory and pro-
resolution activity in experimental dermal inflammation,
glomerulonephritis, and hind limb–induced second or-
gan injury [15–20].
We have previously demonstrated the protective effect
of a stable analog of aspirin-triggered 15-epi-LXA4, 15-
epi-16-(FPhO)-LXA4-Me in experimental murine ARF
in vivo as manifested by significant functional and mor-
phologic protection and by blunted chemokine and cyto-
kine responses [21]. The latter experiments focused on
a relatively small number of mediators that have pre-
viously been implicated in the pathogenesis of ischemia/
reperfusion injury or have been identified as players in
lipoxin-mediated cytoprotection in other systems. While
such targeted approaches can shed valuable new light on
molecular mechanisms of disease, they are, by definition,
biased by and dependent on, previous work in the bio-
logic system of interest or in related systems. With ad-
vances in transcriptomics, it is now apparent that even
simple perturbations of single-cell systems induce com-
plex and highly coordinated changes in gene expression.
By applying these emerging technologies to well-charac-
terized disease models it should be possible to decipher, in
an unbiased fashion, the full spectrum of genomic events
that underpin organ dysfunction and the complex sym-
phony of interrelationships within these disease-related
gene expression networks, ultimately identifying the ge-
nomic switches that direct these responses toward resolu-
tion and repair. Against this background, we have em-
ployed transcriptome profiling using oligonucleotide
microarrays and computational gene annotation in the
present study to identify the profile of genes whose ex-
pression is altered in experimental murine ischemia/
reperfusion injury, and to probe ischemia/reperfusion
injury–modulated genes whose expression levels are fur-
ther influenced by 15-epi-16-(FPhO)-LXA4-Me.
METHODS
Experimental ischemia/reperfusion injury
ARF was induced in National Institutes of Health
(NIH) Swiss mice (25 to 35 g) by clamping both renal
pedicles for 30 minutes, followed by 24 hours of reperfu-
sion [21]. Animals received a 15 g single bolus injection
of 15-epi-16-(FPhO)-LXA4-Me or an equivalent volume
of its vehicle into the inferior vena cava 10 minutes prior
to clamping. Sham-operated animals served as controls.
The influence of the lipoxin analog on changes in renal
function, morphology, and PMN infiltration in these
mice has been previously reported [21]. As a second
model of ARF, murine folic acid–induced acute tubular
necrosis (ATN) was used. This model, as previously de-
scribed [22], involved administering 250 mg/kg body
weight of folic acid by intraperitoneal injection. Animals
were sacrificed at 0, 3, 6, 24, and 72 hours. Serum creati-
nine increased approximately four- to five-fold over the
course of the experiment [22].
Taqman-PCR
Total RNA was isolated from murine kidneys and
spleens using Trizol solution (Gibco, Paisley, UK) ac-
cording to the manufacturer’s instructions. For real-time
polymerase chain reaction (PCR) analysis of murine tis-
sue, chromosomal DNA was removed from total RNA
using DNase I. DNAse-treated RNA (2 g) was tran-
scribed to cDNA using standard procedures. Real-time
PCR was performed on a TaqMan ABI 7700 Sequence
Detection System (Applied Biosystems, Weiterstadt,
Germany) using heat-activated TaqDNA polymerase
(Amplitaq Gold; Applied Biosystems, Weiterstadt, Ger-
many) [23]. After an initial hold of 2 minutes at 50C
and 10 minutes at 95C, the samples were cycled 40 times
at 95C for 15 seconds and 60C for 60 seconds. Target
gene forward and reverse primers and probes were de-
signed using Primer Express 1.5 software (Applied Bio-
systems, Foster City, CA, USA). Commercially available
predeveloped TaqMan assay reagents (PDARs) were
used for the internal standards human glycerin-aldehyde-
3-phosphate-dehydrogenase (GAPDH) and 18S ribo-
somal RNA (18S rRNA). All primers and probes were
obtained from Applied Biosystems, Weiterstadt, Ger-
many. The primers were cDNA-specific, not amplifying
genomic DNA. The following sequence of oligonucleo-
tide primers (300 nmol) and probes (100 nmol) were
used: (1) ADAM8 (forward primer: 5-GCCCCTTGA
ACGCTCCTT-3; reverse primer: 5-TTCCATCCAT
GCAAACCTTTC-3; and probe: 5-TATTGCAGGG
CACCAAGTGCGAGG-3); (2) claudin-1 (forward
primer: 5-GATGTGGATGGCTGTCATTGG -3; re-
verse primer: 5-CCATGCTGTGGCCACTAATGT-3;
and probe: 5-CGCCAGACCTGAAAT-3); (3) clau-
din-3 (forward primer: 5-CATCACGGCGCAGATC
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AC-3; reverse primer: 5-TGCTCTGCACCACGCA
GTT-3; and probe: 5-CATCCACAGGCCCTC-3); (4)
claudin-7 (forward primer: 5-ATGATGAGCTGCAA
AATGTACGA-3; reverse primer: 5-CACCAGGGA
CACCACCATTAA-3; and probe: 5-CCCTGCAGGC
CACT-3); and (5) meprin-1 (forward primer: 5-CAC
AAGAGATGGCCACATACCA-3; reverse primer:
5-CGATAGCGCTCAAAAGCATTG-3; and probe:
5-CAGCTTGGAAATGAAT-3).
Target and housekeeper cDNA templates (GAPDH
and 18S rRNA) were quantified by standard curves of di-
luted standard cDNA. The expression of each target gene
was normalized to both different housekeeping tran-
scripts. All measurements were performed in duplicate.
Controls consisting of ddH2O were negative in all runs.
Oligonucleotide microarray (gene chip) analysis
Twelveg of total RNA were annealed to the T7-(dt)24
primers. First-strand cDNA synthesis was completed by
incubating the mixture with 2 L of Superscript II RT
(20,000 units) at 42C for 1 hour. Second-strand synthesis
was carried out in a total volume of 150 L. Following
purification, the cDNA pellet was precipitated with am-
monium acetate and resuspended in RNAse-free water.
Synthesis of cRNA was performed by in vitro transcrip-
tion. The amplified cRNA was purified with an affinity
resin column. The cRNA was fragmented and hybridized
to the Affymetrix GeneChip Murine U74Av2 array
(Santa Clara, CA, USA), permitting the assessment of
the abundance of approximately 12,500 mRNA tran-
scripts representing known genes and ESTs. Hybridiza-
tion proceeded overnight. Subsequent washing and stain-
ing of the arrays was carried out using the Affymetrix
GeneChip fluidics station protocol EukGE-WS2 (Santa
Clara, CA, USA). Following washing and staining, the
probe arrays were scanned twice at 3 m resolution
using the Affymetrix GeneChip System confocal scanner
(Santa Clara, CA, USA).
Data analysis was performed using Affymetrix Gene-
Chip software (Santa Clara, CA, USA). The criteria
used to identify significant differential regulation of the
transcripts was a greater than 2.0-fold change in expres-
sion in replicate experiments.
Bioinformatic annotation of unknown sequences
cDNA sequences which did not show homology with
known genes by Basic Local Alignment Search Tool
(BLAST) search against the nonredundant database
were used as input into an annotation pipeline. Briefly,
the annotation pipeline consisted of serial stages of ho-
mology searching, using BLAST and position-specific
iteration (PSI)-BLAST searches of the high-throughput
genomic sequence databases to identify genomic clones
[24, 25]. The identified clones were used in GENSCAN-
based sequence topography analysis to identify gene fea-
tures such as introns, exons, and promoter regions [26].
Having determined the sequence of the gene, the amino
acid sequence of corresponding proteins was deduced by
open reading frame analysis. The amino acid sequences
were thus assembled further by homology searching of
the existing protein databases and structural modeling
of the protein to identify conserved structural motifs or
structural domains shared by other proteins. For protein
structural analysis, the structure prediction meta server
was employed [27]. This is an integrated platform for
the utilization of a number of high-quality structure pre-
diction servers and permits identification of conserved
sequences by comparison with the Structural Classifica-
tion of Proteins (SCOP) database [28].
RESULTS AND DISCUSSION
Oligonucleotide microarrays identify claudin-1, -3,
and -7, and ADAM8 among 226 known genes whose
mRNA levels are increased in response to
experimental murine renal ischemia/reperfusion injury
To reduce the impact of background physiologic inter-
animal variation on mRNA levels, total RNA was pooled
from three individual animals from sham-operated and
ischemia/reperfusion injury animal groups. Oligonucleo-
tide microarray analyses were performed in duplicate
with a correlation coefficient between experiments of
0.92. Of a total of 12,488 genes displayed on the microar-
ray, 6795 (54%) were expressed in the kidney under
basal conditions. Of these, 1016 were altered following
ischemia/reperfusion injury, 445 of which had expression
changes of two-fold or greater. Two hundred twenty-six
known genes were found to be up-regulated. Table 1
shows changes in several functional classes of genes im-
plicated in the pathogenesis of ischemic ARF that are
candidate targets for lipoxin-mediated renoprotection,
including chemoattractants, cytokines, chemokines and
chemokine receptors (e.g., interleukin-6, GRO-1, inter-
feron-, and C-C receptor 1); growth factors and related
molecules (e.g., thrombospondin-1 and early growth re-
sponse gene 1); adhesion molecules (e.g., intercellular
adhesion molecule-1); cell cycle and apoptosis-related
genes (e.g., 14-3-3- and annexin III); transcription fac-
tors (e.g., ATFx); proteases (e.g., lipocalin-2); and cy-
toskeletal proteins (e.g., -tubulin).
Among the molecules previously implicated in the
pathogenesis of ischemic ARF whose mRNA levels were
increased with microarray analysis are the adhesion mol-
ecules ICAM-1 and vascular cellular adhesion mole-
cule-1 (VCAM-1), the cell cycle inhibitors p21 and 14-3-
3-sigma, and an EST homologous to rat kidney inducible
molecule-1 (KIM-1) [29–31]. These served as positive
controls for the system. Of interest was the coordinated
up-regulation of three members of the claudin family,
claudins 1, 3, and 7. Claudins are tight junction integral
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Table 1. Identification of claudin-1, -3, and -7, and ADAM8 among other genes whose mRNA levels are increased in response to experimental
renal ischemia/reperfusion injury, as determined by oligonucleotide microarray analysis
Fold change in mRNA levels
GenBank
Accession Gene OM1a OM2a
Chemoattractants, cytokines, chemokines and chemokine receptors
X54542 Interleukin-6 2.5 5.0
U49513 Small inducible cytokine A9 (MIP-1) 5 11.5
J04596 GRO-1 4.3 11.3
U41341 Endothelial monocyte-activating polypeptide-1 3.3 3.5
V00755 IFN- fibroblast 3 2.8
X16834 Mac-2 antigen 10.4 11.4
U29678 C-C receptor 1 12.5 5.0
X59769 IL-1 receptor type 2 3.6 7.0
X57796 TNF receptor member 1 2.4 14.1
U69599 IFN gamma receptor type 2 6.3 11.6
Growth factors and related molecules
D25540 TGF type 1 receptor 2.4 2.2
M62470 Thrombospondin-1 4.3 4.9
M28845 Early growth response gene 1 7.8 9.3
Adhesion molecules
M90551 ICAM-1 3.2 4.3
M94487 VCAM-1 3.7 10.0
AF072127 Claudin-1 4.8 5.9
AF095905 CPETR2 (claudin-3) 4.5 2.7
AF087825 Claudin-7 7.1 5.2
AA986114 KIM-1 (rat homologue) 14.3 15
X14432 Thrombomodulin 4.3 5.6
Cell cycle, apoptosis, heat shock proteins, and other mediators of oxidative stress
AF058798 14-3-3 protein sigma 9.9 19.5
AF017128 Fos-like antigen 1 4.4 14.1
M12571 Heat shock protein 70 kD 3 11.3 9.1
AB020886 SSeCKS 15.3 35.2
U09507 Cyclin-dependent kinase inhibitor1A (p21) 9.8 16.8
V00835 Metallothionein 1 5.2 3.9
X68273 CD68 6.4 4.6
D14077 Clusterin 5.3 3.5
X13333 CD14 5.6 5.1
M69260 Lipocortin1 5 4.9
AJ001633 Annexin III 11.3 22.5
L31958 pMAT1 (clone) 15.2 41.7
Transcription factors and other modulators of cell signaling
AB012276 ATFx 4.1 4.0
U19118 LRG-21 5.0 4.5
Proteases
X81627 Lipocalin-2 64.8 42.9
Cytoskeletal
X04663 Beta-tubulin, Mbeta 5 50.4 42.4
X13297 Vascular smooth muscle, -actin 12.4 11.3
M14044 Calpactin 1 heavy chain (p36) 8.1 5.9
Matrix proteins or components and modulators of cell matrix
X56304 Tenascin C 8 8.7
Z68618 Transgelin 3.9 4.8
U03715 Procollagen, type XVIII, alpha 1 9.9 4.8
Z31362 (Balb/C) Tx 01 8.3 7.2
Miscellaneous
U77630 Adrenomedullin 3.8 2.6
X13335 ADAM8 5.5 13.3
Abbreviations are: IFN-, interferon beta; IL-1, interleukin-1; TNF, tumor necrosis factor; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cellular
adhesion molecule-1; CPETR2, clostridium perfringens enterotoxin receptor 2; KIM-1, kidney inducible molecule-1; SSeCKS, SrC-suppressed C kinase substrate;
ATFx, expression of a specific mouse gene; ADAM8, a disintegrin and metalloproteinase domain protein 8.
a Oligonucleotide microarrays (OM) analyzed RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals, fold change reflecting expression in ischemia/
reperfusion injury animals using sham as baseline for comparison
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Fig. 1. Confirmation by real-time polymerase chain reaction (RT-
PCR) of differential expression of oligonucleotide microarray-identified
genes in experimental ischemia/reperfusion injury in murine kidneys
in vivo and modification of expression by 15-epi-16-(FPhO)-LXA4-Me.
RT-PCR confirms up-regulation of claudin-1, claudin-3, claudin-7, and
ADAM8, and down-regulation of meprin-1 in murine kidneys har-
vested from mice with experimental ischemia/reperfusion injury ( ) as
compared to sham-operated controls () and modification of expression
by 15-epi-16-(FPhO)-LXA4-Me (). Expression data is shown as ratio
to 18SrRNA (y axis shows ratio to rRNA).
membrane proteins [32]. To date, 24 members of the
claudin gene family have been described [32]. Within
the kidney, claudins form an important part of tight
junctions, as vividly highlighted with the reporting that
mutations in claudin-16 (paracellin-1), which is exclu-
sively expressed in the thick ascending limb of Henle,
are associated with hereditary hypomagnesemia [33].
Damage to tight junctions resulting in impaired cell-cell
adhesion and disruption of the permeability barrier are
features of epithelial cell damage in ischemic acute renal
failure [34].
To confirm the differential expression of these key
modulators of barrier integrity, real-time PCR was per-
formed with RNA extracted from the kidneys of animals
with ischemia/reperfusion injury (Fig. 1). Under basal
conditions mouse kidneys expressed little mRNA for
claudin-1, whereas mRNA levels were significantly en-
hanced following ischemia/reperfusion injury. Similarly,
low expression of claudin-3 was seen in sham-operated
animals, whereas claudin-3 mRNA levels were signifi-
cantly enhanced in ischemia/reperfusion injury. Clau-
din-7 expression was also induced in the latter setting.
Real-time PCR demonstrated fold increases of 6.97, 4.71,
and 9.24 for claudin-1, -3, and -7, respectively, confirming
the data obtained with oligonucleotide microarrays.
Messenger RNA levels for several other claudins (clau-
din-8 and -6) and tight junction proteins (occludin and
junctional adhesion molecule) expressed by the kidney
were not perturbed during ischemia/reperfusion injury
(data not shown), while mRNA for claudin-2 was sup-
pressed [1.9-fold on both oligonucleotide microarrays
(OM), not reaching cutoff levels used for this analysis],
suggesting differential regulation of gene expression in
this setting. The finding of higher mRNA levels for clau-
din-1, -3, -7 in the context of ischemia/reperfusion injury
is intriguing given the dramatic changes in epithelial po-
larity and adhesion that typifies ischemic ATN [3]. In-
deed, recent studies have suggested additional dynamic
roles for claudins as modulators of cell signaling and
the actin cytoskeleton [32]. Claudin proteins, including
claudin-1 perturbed during ischemia/reperfusion injury
in the present study, have been shown to recruit mem-
brane-type matrix metalloproteinases (MT-MMPs), in-
cluding promatrix metalloproteinase-2, enhancing acti-
vation of pro-MMP-2 in vitro [35]. Together these
observations raise the possibility of a role for claudins
in tissue remodeling in ischemic ARF.
In light of the perturbations in claudin expression de-
scribed above and their potential role in regeneration
and repair, it is noteworthy that renal mRNA levels for
a disintegrin and metalloproteinase domain protein 8
(ADAM8) were also enhanced in experimental IRI. This
finding was confirmed by real-time PCR analysis (Fig.
1). The ADAM gene family is composed of proteins that
have transmembrane and cytoplasmic domains com-
posed of MMP-like, disintegrin-like, cysteine-rich, and
epidermal growth factor (EGF)-like (snake venom
MMP-like) domains. ADAM family members have been
implicated in cell fusion, cell-to-matrix adhesion, and
proteolytic degradation of extracellular matrix, [36] and
can modulate cell signaling systems which are key for
normal cellular processes such as cell morphogenesis,
wound healing, and tumor cell invasion [37].
Changes in renal mRNA levels following ischemia/
reperfusion injury could represent ischemia/reperfusion
injury–triggered changes in the renal parenchymal tran-
scriptome, infiltration of renal parenchyma by leuko-
cytes, or a combination of these events. In this regard,
it is noteworthy that neither claudin-1 nor ADAM8 were
expressed in splenic tissue harvested from sham-oper-
ated and ischemia/reperfusion injury animals, as assessed
by RT-PCR, suggesting that the increase in their renal
mRNA levels in ischemia/reperfusion injury reflected
perturbation of the transcriptome of resident renal cells.
Oligonucleotide microarrays identify epidermal growth
factor and meprin-1 among 112 known genes whose
mRNA levels are decreased in response to
experimental ischemia/reperfusion injury
Of the 445 transcripts (25%) whose mRNA levels were
altered two-fold or greater in experimental ischemia/
reperfusion injury, 112 were down-regulated. Among the
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Table 2. Identification of meprin-1 among other genes whose expression is suppressed in response to experimental murine
renal ischemia/reperfusion injury
Fold change in mRNA levels
GenBank
Accession Gene OM1a OM2a
Chemoattractants, cytokines, chemokines and chemokine receptors
L12030 Stromal cell-derived factor 1 (CXCL12) 2 2.1
D17444 Leukemia inhibitor factor receptor 3.8 2.5
Growth factors
U22516 Angiogenin 3.0 3.8
M30641 Fibroblast growth factor-1 2.7 2.3
V00741 Epidermal growth factor 8.8 5.4
M34094 Midkine 2.6 2.6
Adhesion molecules
AB010144 Mitsugumin 29 2.2 2.1
Cell cycle, apoptosis, heat shock proteins, and other mediators of oxidative stress
X98055 Glutathione-S-transferase theta 1 6.3 11.6
AF159298 Nucleotide phosphodiesterase (Pde1a7) 4.1 3.5
Proteases and dipeptidases
L15193 Meprin-1 18.9 10.7
AJ131851 Cathepsin F 3.5 2.7
D13139 Dipeptidase 1 4 3.8
Cytoskeletal
M21828 Growth arrest specific 4.7 3.7
U04354 Adseverin 3.2 3.0
Matrix proteins
Z35167 Procollagen, type IV,  4 2.4 12.8
Transport proteins
U38652 Solute carrier family 22, member 1 3.0 2.5
X77241 Solute carrier family 17, member 1 2.2 2.0
D88533 NBAT 2.1 2.3
L02914 Aquaporin 1 2.5 2.6
U73521 Solute carrier family 1, member 1 2.5 2.0
AF058054 Solute carrier family 16, member 7 2.1 2.4
AF075261 Orphan transporter (Xtrp3) 2.7 2.4
AJ012754 Solute carrier family 7, member 7 2.7 2.8
Miscellaneous
U42443 MECA39 4.8 5.2
AB005141 Klotho 2.8 2.8
a Oligonucleotide microarrays (OM) were performed with RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals, fold change reflecting expression
in ischemia/reperfusion injury using sham as baseline for comparison
major families of genes whose mRNA levels were sup-
pressed were chemoattractants, cytokines, chemokines
and chemokine receptors (e.g., stromal cell derived fac-
tor-1 and leukemia inhibitory factor receptor; growth
factors [e.g., EGF, angiogenin, and fibroblast growth fac-
tor]; adhesion molecules (e.g., mitsugumin 29); cell cycle-
and apoptosis-related genes (e.g., glutathione-S-trans-
ferase 	1); proteases (e.g., meprin-1; and cytoskeletal
proteins (e.g., adseverin) (Table 2).
In keeping with previous reports, renal expression of
EGF was transiently decreased after ischemia/reperfusion
injury, further validating the approach [38]. A noteworthy
finding was down-regulation of meprin-1 (meprin B).
Suppression of meprin-1 was confirmed by real-time
PCR analysis of RNA from the kidneys of sham-oper-
ated and ischemia/reperfusion injury animals (Fig. 1).
Normal mouse kidney displays strong detectable meprin
transcript levels, the expression of which is blunted in the
injured kidney. Meprins (A and B) are zinc metalloendo-
peptidases expressed by renal proximal tubules and brush
border membranes of the intestine [39]. Meprin A is com-
posed of homodimers of  subunits, whereas meprin B
is a heterodimer of  and  subunits. Meprins  and 
subunits have markedly different substrate and peptide
bond specificity, meprin  preferring substrates with
small or hydrophobic residues while meprin  selects for
acidic amino acids, such as those found in the peptide
hormone gastrin [40]. Meprin A inhibition has been de-
scribed as protective in ischemia/reperfusion injury [41],
while little is known about meprin B in ischemia/reperfu-
sion injury. Meprins are the only known endopeptidases
in brush border membranes that degrade proteins. Inter-
estingly, down-regulation of meprin-1 has been recently
reported in experimental hydronephrosis, suggesting that
diverse renal insults modulate the expression of this en-
dopeptidase in vivo [42].
Real-time PCR analysis of mRNA levels in mice with
folic acid–induced ATN also demonstrated increased
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Fig. 2. Confirmation by real-time polymerase chain reaction of differential
expression of oligonucleotide microarray-identified genes in experimental
acute tubular necrosis in murine kidneys in vivo. (A through D) RT-
PCR confirms up-regulation of claudin-1, claudin-3, claudin-7, and
ADAM8 and (E ) down-regulation of meprin-1 in murine kidneys (N

3) harvested from mice with folic acid induced acute tubular necrosis
(ATN). A time course with 0, 3, 6, 24, and 72 hours after folic acid is
shown. Expression data is shown as ratio to 18S rRNA (y axis shows
ratio to rRNA).
levels for claudin-1, -3, and -7, and ADAM8, and de-
creased meprin-1 mRNA levels, suggesting that these
events are common to both ischemic and nephrotoxic
ATN (Fig. 2).
Bioinformatic annotation of cDNAs corresponding to
transcripts without homology to known genes
identifies a further cohort of genes whose expression
is altered in experimental ischemia/reperfusion injury
Of the 445 renal transcripts altered in response to
ischemia/reperfusion injury, 107 corresponded to ESTs
without homology to known genes, as determined by
standard database search strategies of the human and
murine genome databases. The annotation of these tran-
scripts remains a major obstacle to the streamlined analy-
sis of data derived from commercial microarrays. To
further characterize these transcripts we employed a
Fig. 3. Serum creatinine levels assessed after 24 hours of reperfusion.
N 
 3 for sham-operated controls, 15-epi-16-(FPhO)-LXA4-Me (15 g/
mouse), and vehicle-treated acute renal failure (ARF). Modified from
Leonard et al, J Am Soc Nephrol 13:1657–1662, 2002.
computational gene annotation pipeline as described in
the experimental procedures. These studies have led to
the identification of a further 24 genes whose expression
is altered in response to renal ischemia/reperfusion in-
jury, a representative cohort of which are detailed in
Table 3. The unknown sequences identified in the mi-
croarray experiment were used as input to the annotation
pipeline. Typical of such analysis was the EST AI836034,
found to be up-regulated 2.1- and 2.3-fold on oligonucleo-
tide microarrays 1 and 2, respectively. First, the sequence
was retrieved using the ENTREZ sequence retrieval sys-
tem at the National Centre for Biotechnology Informa-
tion. This EST, UI-M-AQ0-aad-f-06-0-UI.s2, when com-
pared to the nonredundant nucleotide databases this
sequence produced no significant homology to any known
gene. However this sequence was 99% identical to a
998-nucleotide cDNA clone from adult mouse brain,
clone:0710007K04. To determine the genomic structure
of this sequence, GENSCAN analysis of the clone topog-
raphy was completed. This algorithm identifies features
such as introns, exons, and promoter regions in genomic
sequence. Analysis of cDNA clone:0710007K04 demon-
strated the presence of a 218 amino acid single exon
protein. The EST sequence used as input was contained
within the predicted open-reading frame of the cDNA,
positioned in the 5 untranslated region adjacent to the
amino acid sequence. Pairwise alignment was performed
with the EST and cDNA sequences to confirm the pre-
dicted location. The amino acid sequence thus generated
was then compared to the nonredundant protein data-
base, where a substantial homology was found to a hu-
man protein similar to enigma (LIM domain protein)
(GenBank accession no. AAH14521). Enigma proteins
are a family of cytoplasmic proteins that possess a PDZ
domain at the amino terminal and one to three Lun-11
Isle-1 mec-3 (LIM) domains at the carboxyl terminal. By
virtue of these two protein interacting domains, enigma
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Table 3. Bioinformatic annotation of cDNAs corresponding to transcripts without homology to known genes by BLAST search whose
expression is altered in response to experimental murine renal ischemia/reperfusion injury
Fold change in mRNA level
GenBank
Accession Gene annotation OM1a OM2a
Induced transcripts
AI132207 Eukaryotic translation initiation factor 1A 4.2 2.1
AW122030:d Phosphoserine aminotransferase 2.3 2.1
AA270365 Beta-1,4 mannosyltransferase 2.2 5.5
AW122864 RNA polymerase II, polypeptide H 2 2.1
AW045413 DNA polymerase delta subunit 3 6
AI845934 EBNA1 binding protein 2 2.1 2.1
AI509617 Mitochondrial ribosomal protein S18b 2.1 2.7
AW060179 Zw10 interactor 2.1 2.0
AI836034 Enigma (LIM domain protein) 2.3 2.1
AI841914 Acyl CoA binding protein 2.8 2.3
Suppressed transcripts
AW050325 Crystallin, lamda 1 2 2.3
AA656014 Transmembrane 7 superfamily, member 1 2.1 2.2
AW124932 3-oxoacid CoA transferase 2.4 2.1
AA675075 Kidney and liver proline oxidase 1 2.8 3.7
NP011467 Sepiapterin reductase 2.4 2.6
AI845337 Quinoid dihydropteridine reductase 2.1 2.0
AI840094 Androgen-inducible aldehyde reductase 2.1 2.2
AW211207 Cgi-18 protein (asc-1 complex subunit p50) 3 2.0
AV334517 Biphenyl hydrolase-related 2.3 2.3
AI842259 Pyruvate dehydrogenase kinase, isoenzyme 3 2.4 2.4
AW121801 Adenosine kinase 2.4 2.1
AI314227 Aspartoacylase aspa 3.2 2.1
AI852646 Aminoacylase-1 2.7 2.0
AW123061 Never in mitosis gene A-related kinase 2 2.5 2.4
a Oligonucleotide microarrays (OM) were performed with RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals
proteins are capable of protein-protein interactions. It
has been proposed that enigma proteins may act as
adapters between kinases and the cytoskeleton [43]. This
general approach was used to identify 10 up-regulated
and 14 down-regulated genes in experimental renal isch-
emia/reperfusion injury.
Modulation of the renal transcriptomic response to
ischemia/reperfusion injury by
15-epi-16-(FPhO)-LXA4-Me
We have previously demonstrated a protective effect
of a lipoxin-stable analog 15-epi-16-(FPhO)-LXA4-Me
in renal ischemia/reperfusion injury, establishing the
therapeutic potential of lipoxin and ATL analogs in this
setting (Fig. 3) [21]. The renoprotective effect of 15-epi-
16-(FPhO)-LXA4-Me was associated with reduced PMN
infiltration and modulated intrarenal cytokine expres-
sion. The finding of reduced mRNA levels for interleu-
kin-1 (IL-1), IL-6 and GRO-1 in lipoxin-treated animals
in association with increased expression of suppressors
of cytokine signaling (SOCS) -1 and SOCS-2 suggests
that a complex interplay of transcriptional events un-
derpin the renoprotective effect of lipoxin in experimen-
tal ischemia/reperfusion injury [21]. To further define
the molecular events associated with renoprotection we
performed oligonucleotide microarray-based compari-
son of mRNA expression profiles in the ischemia/reper-
fusion injury kidneys in the presence and absence of
15-epi-16-(FPhO)-LXA4-Me. For the purposes of this
analysis, ischemia/reperfusion injury–associated gene ex-
pression levels served as basal levels and lipoxin-medi-
ated changes were expressed as fold change relative to
this baseline parameter. Pretreatment with lipoxin ana-
log resulted in a blunting of ischemia/reperfusion injury–
associated gene induction (Tables 4 and 5). This effect
was observed in all of the functional classes of genes
induced by ischemia/reperfusion injury, including in-
flammatory mediators such as chemoattractants, cyto-
kines, chemokines and chemokine receptors, growth fac-
tors, adhesion molecules, and other genes. This marked
attenuation in both the magnitude and spectrum of gene
expression changes applied to genes typically expressed
by infiltrating leukocytes (e.g., CD14 and lipocortin 1)
and to genes whose expression is most abundant in resi-
dent epithelial cells (e.g., claudins, KIM-1).
In addition to attenuating proinflammatory responses
induced by a range of important mediators, lipoxins, ATLs,
and their analogs actively promote resolution of inflamma-
tion by promoting macrophage clearance of apoptotic
neutrophils and by stimulating the release of cytokines
and growth factors implicated in tissue remodeling and
repair [e.g., transforming growth factor (TGF) beta] [3, 4].
In a second analysis we investigated whether lipoxin
treatment was associated with modulation of the expres-
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Table 6. Genes whose mRNA levels were not altered in response to experimental renal ischemia/reperfusion injury but were altered
significantly by lipoxin analog
Fold change in mRNA levels
Ischemia/reperfusion Lipoxin vs. ischemia/
GenBank injury vs. Shamb reperfusion injuryc
Accession Gene OM1a OM2a OM1a OM2a
M15268 Aminolevulinic acid synthase 2, erythroid 1.8/1.1 4.9/3.9
U49915 Adipocyte specific protein adipoQ 1.2/1.2 4.2/3.1
U96684 Paired-Ig-like receptor A3 1.8/1.5 2.8/3.4
V00722 Mouse gene for -1-globin 1.5/1.5 3.0/2.4
X04673 Adipsin 1.4/1.2 7.0/19.1
D67076 ADAMTS1 1.6/1.9 2.2/2.2
AB017615 Eos protein 1.7/1.0 3.1/2.2
a Oligonucleotide microarrays (OM) analyzed RNA pooled from 3 sham and 3 ischemia/reperfusion injury animals
b Fold change reflecting expression in ischemia/reperfusion injury animals using sham as baseline for comparison
c Fold change reflecting expression in lipoxin-treated using ischemia/reperfusion injury as baseline for comparison
sion of a cluster of genes that was not perturbed by
ischemia/reperfusion injury alone and could represent
a lipoxin-stimulated renoprotective genomic program.
To this end, 5779 of the total number of 6795 renal-
expressed genes displayed on the microarray (80%) were
not perturbed by ischemia/reperfusion injury alone. Of
these, 7 known genes (0.12%) were perturbed by two-
fold or more during lipoxin treatment on both micro-
arrays, 6 genes being induced and 1 gene being suppressed
(Table 6). The relatively small number of lipoxin-respon-
sive, ischemia/reperfusion injury–independent genes iden-
tified in this analysis, in comparison to the striking modu-
lation of ischemia/reperfusion injury–associated genes,
suggests that the lipoxin analog conferred renoprotec-
tion either by inhibiting a pathogenic event, yet to be de-
fined at the core of ischemia/reperfusion injury, or that the
analog had dramatic effects on gene expression by virtue
of its ability to influence several key pathophysiologic
events in parallel, such as vascular tone, leukocyte recruit-
ment and clearance, and cytokine responses. Most lipoxin-
mediated effects reported to date are mediated through
engagement of specific G protein–coupled lipoxin recep-
tors [5]. LXA4 also modulates activation and transactiva-
tion of growth factor receptors [13]. Our data do not
exclude a role for these events at different time points
throughout the course of ischemia/reperfusion injury.
It was striking in the present study that the lipoxin
analog prevented ischemia/reperfusion injury–induced
changes in mRNA levels for most genes and was not
limited to a specific family or families of genes. This obser-
vation suggests that the lipoxin analog modulated a single
pathophysiologic event at the core of ATN and related
downstream processes or modulated a number of impor-
tant events in parallel. The latter would appear most likely,
given the compelling evidence from in vitro systems that
lipoxin can influence a variety of pathobiologic functions
that are relevant to ischemic ATN, including vascular
tone, epithelial cell injury, cytokine release, and leukocyte
recruitment and clearance (vide supra).
CONCLUSION
The ischemia/reperfusion injury–associated and reno-
protective transcriptomic changes described herein will
provide the template for further dissection of the molecu-
lar component of renal injury by ischemia/reperfusion in-
jury and other insults in vitro and for the elucidation of
novel mechanisms of renoprotection in renal disease.
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